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Abstract
Purpose In addition to guidelines focusing on scientific evidence, practical recommendations on fertility preservation are 
also needed.
Methods A selective literature search was performed based on the clinical and scientific experience of the authors. This 
article (Part II) focuses on fertility preservation techniques. Part I, also published in this journal, provides information on 
disease prognosis, disease-specific therapy, and risks for loss of fertility.
Results Ovarian stimulation including double stimulation and freezing of oocytes is the best-established therapy providing 
live birth chances in women < 35 years with high ovarian reserve of around 30–40%. Ovarian tissue freezing is especially 
useful in young women with good ovarian, if spontaneous conception is favoured and if < 1 week until chemotherapy is 
provided. Data on success rates are still limited, but this further evolving technique will possibly reach similar success rates 
as ovarian stimulation. GnRH agonists seem to reduce the risk of premature ovarian failure up to 50%; however, the effect is 
possibly not long-lasting. Ovarian transposition can easily be combined with freezing of ovarian tissue and is the preferred 
technique before pelvic radiotherapy. Other techniques, such as in vitro maturation, are limited to women with high ovar-
ian reserve and remain less effective. In addition, procedures such as in vitro growth of follicles, etc. are still experimental.
Conclusions Fertility preservation in women provides realistic chances of becoming pregnant. The choice of technique 
needs to be based on the time required, the woman’s age, its risks and efficacy, and the individual preference of the patient.
Keywords Fertility preservation · Ovarian tissue · Oocyte ovarian stimulation · GnRH agonists
Introduction
Increasing survival rates in patients affected by oncologi-
cal disease and advances in reproductive medicine have led 
to the development and increasing use of various fertility 
preservation techniques. Meanwhile, improving data and 
optimization of the available techniques have allowed a 
realistic portrayal of the efficacy and risks of the most com-
monly used methods, as well as recommendations for the use 
of the techniques, alone or in combination. Several guide-
lines and recommendations have been published in Europe 
[1], the United States [2], and elsewhere. These guidelines 
mainly focus on scientific evidence, but are less practically 
orientated.
We have, therefore, prepared an update of practical rec-
ommendations published in 2011 by the FertiPROTEKT 
network, a network and society of physicians and biologists 
specializing in fertility preservation in Germany, Austria, 
and parts of Switzerland [3].
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As the topic has become too broad for one single paper, 
we have prepared two articles. Part I focuses on the diseases 
and provides information essential in decision making for 
or against fertility preservation, such as prognosis of the 
disease and disease-specific therapy and risks for loss of fer-
tility. In this second article, Part II, we provide recommen-
dations specifically on the fertility preservation techniques.
Ovarian stimulation and freezing of oocytes
Background
The decisive factor in ovarian stimulation is maximization of 
the oocyte yield and minimization of the complication rate, 
so that oncological treatment can be started immediately 
after follicular aspiration. It should be noted that fertilized 
oocytes can only be transferred to the woman after the con-
sent of both partners, which is why preserving some oocytes 
in an unfertilized state should be considered, even in the 
case of a stable partnership. Ovarian stimulation can now 
be initiated at any time during the menstrual cycle [4–7]. 
In addition, double stimulation [8] and stimulation directly 
after ovarian tissue removal are also possible [9].
Efficacy
The number of oocytes collected depends on the age of the 
patient and the underlying ovarian reserve, which varies 
individually. According to the FertiPROTEKT registry, the 
mean number of oocytes collected in 809 women according 
to age was ≤ 30 years 12.9, 31–35 years 12.3, 36–40 years 
9.0, and 5.7 in women aged > 40 years [10].
Using the number of oocytes which were collected 
prior to chemotherapy and successfully fertilized, a Ferti-
PROTEKT study [11] calculated the theoretical birth rate 
depending on the age of the woman using 125 follicular 
aspirations (Table 1). First case series confirm these calcu-
lated success rates. In 90 women who had cryopreserved 
oocytes, 196 embryo transfers were performed, which led to 
the birth of 35 children (birth rate 38.9% per patient) [12]. 
Since the number of frozen oocytes is decisive for the later 
chances of conception, double stimulation could increase 
the number of cells.
Cryopreservation of oocytes is now usually performed 
by vitrification. Rienzi et al. [13] compared oocytes that 
were directly fertilized after removal and freshly transferred 
or those that were previously cryopreserved in an unferti-
lized state. Pregnancy rates were not significantly different. 
These data were confirmed in a later meta-analysis [14]. The 
effectiveness of oocyte vitrification has also been confirmed 
in cancer patients [15]. In 11 women whose oocytes were 
removed before gonadotoxic therapy at an average age of 
35.6 years (30–41 years), thawed, and fertilized, the oocyte 
survival rate was 92%, the fertilization rate 77%, and the 
implantation rate 32%. A pregnancy occurred in 7 of the 11 
women and a live birth resulted in 4 (36%).
Risks
Ovarian stimulation can lead to side effects caused by the 
medication, as well as complications during the puncture. 
However, clinically relevant bleeding during follicular aspi-
ration or inflammation is rare. High-grade overstimulation 
amongst FertiPROTEKT network patients occurred only 
once in 708 stimulations [6].
Practical approach
The standard protocol for stimulation is the antagonist proto-
col with ovulation induction using GnRH agonists (triptore-
lin 0.2 mg s.c.) to minimize the risk of ovarian hyperstimula-
tion syndrome (OHSS) [16].
Random start stimulation (Fig. 1)
Ovarian stimulation can be started at any time (“random 
start stimulation”) [4–7]. According to a study by Kuang 
et al. [17], pregnancy rates after stimulation start in the luteal 
phase are similarly high to those after a stimulation start in 
the early follicular phase and the malformation rate is unaf-
fected [18]. According to studies to date, stimulation with 
stimulation starting in the luteal phase takes 1–2 days longer, 
and a slightly higher gonadotrophin dose is required per day 
than for a stimulation start in the early follicular phase [6, 7].
Depending on the cycle phase, stimulation can be carried 
out as follows (Fig. 1):
• Stimulation start in the early to mid follicular phase: the 
conventional antagonist protocol with HMG or FSH, 
addition of the antagonist when control follicle ≥ 14 mm 
and GnRH-agonist triggering with triptorelin 0.2 mg s.c. 
when 3 follicles ≥ 17 mm. Stimulation dose is approx. 
50 IU higher than for an intended fresh transfer.
Table 1  Estimated live birth rate after ovarian stimulation, based on 
the number of retrieved oocytes and registry data ([11], modified)
Age of the 
women at the 
time of ovarian 
stimulation
Median number 
of collected 
oocytes
Median number 
of fertilized 
oocytes
Estimated live 
birth rate (%)
< 26 13.5 8.6 40
26–30 11.3 7.3 35
31–35 11.0 6.1 30
36–40 8.3 5.1 25
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• Stimulation starts in the late follicular phase with a 
leading follicle ≥ ca. 14 mm: ovulation induction with 
follicular size of ca. 14 mm with triptorelin 0.2 mg s.c. 
followed by luteal phase stimulation immediately after 
ovulation.
• Stimulation start in the luteal phase: the conventional 
antagonist protocol with hMG or FSH and GnRH-agonist 
triggering with triptorelin 0.2 mg s.c. Stimulation dose 
is slightly higher than after stimulation start in the early 
follicular phase. Start of antagonists as soon as the newly 
developed leading follicle is ≥ around 14 mm.
Double stimulation
In double stimulation [8], stimulation with a classical antag-
onist protocol as well as ovulation induction with a GnRH-
agonist is initially performed. It can be assumed that the first 
stimulation can also be started in any cycle phase (random 
start stimulation). Small follicles are not aspirated. A second 
stimulation is started around 5 days later. To exclude prema-
ture ovulation, GnRH antagonists are administered as soon 
as the leading follicle exceeds 14 mm. The time required for 
double stimulation is ca. 30 days.
Reducing the estradiol concentration in estrogen‑sensitive 
tumours
To reduce the increasing estrogen concentrations during 
ovarian stimulation, the addition of aromatase inhibitors, 
e.g., letrozole 5 mg (2.5 mg each morning and evening 
from the first day of stimulation) is recommended [19]. The 
number of mature oocytes obtained and their fertilization 
capacity is not reduced by the addition of letrozole [5]. The 
previous studies have not shown increased malformation 
rates in children after low dose stimulation with letrozole 
[20].
Combination of ovarian stimulation with the removal 
of ovarian tissue
Ovarian stimulation can be combined with cryopreservation 
of ovarian tissue to increase the success rate after highly 
gonadotoxic treatment (Fig. 2) [9, 21]. 50% of an ovary is 
removed laparoscopically and ovarian stimulation is started 
1–2 days later. According to the studies carried out so far, 
there is no increased complication risk and the number of 
oocytes obtained is not significantly reduced after removal 
of ovarian tissue. The time required for the combination of 
both treatments is about 2.5 weeks.
Fig. 1  Ovarian stimulation in 
the early, mid, late follicular, 
and luteal phases ([5], modified)
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Cryopreservation and transplantation 
of ovarian tissue
Background
If there is a sufficiently high ovarian reserve, part of the 
ovarian tissue can be cryopreserved for later transplanta-
tion. Since the cryopreserved tissue volume is not very large 
and some of the follicles degenerate during cryopreserva-
tion and transplantation, the transplants are only active for a 
few years. Therefore, the transplant does not serve to restore 
long-term ovarian function, which would replace hormone 
replacement therapy, but only to achieve a pregnancy. Trans-
plantation for the induction of puberty [22, 23] as well as 
postponement of the menopause [24] have been reported; 
however, since transplantations for these indications are of 
limited use endocrinologically [25], the cryopreservation of 
ovarian tissue should only be performed to establish a fertil-
ity reserve.
In principle, the higher the ovarian reserve (i.e., the fol-
licle density in cryopreserved and transplanted ovarian tis-
sue), the greater the chances of pregnancy; therefore, cryo-
preservation of ovarian tissue is ideal for younger women or 
even children. The upper age limit is often stated as 35 years, 
although this limit can be around 38 years for women with 
a high ovarian reserve.
Efficacy
The data for assessing effectiveness are still limited. How-
ever, since data from previously published case series show 
similar success rates, the probability of birth per transplant 
can already be roughly estimated.
In a case series from Denmark with 41 women, 53 trans-
plantations were performed [26]. A total of 42 transplants 
were performed in 32 women because of a wish to conceive. 
31% of transplanted women gave birth to at least one child.
In a case series from the FertiPROTEKT network, 95 
transplants were performed in 74 women [27]. A sub-anal-
ysis of the 40 women who received their first transplant for 
POI included 11 pregnancies and 9 births. This corresponds 
with birth rate of 23% per transplant.
According to data from Denmark, some pregnancies 
are generated after repeated transplantations; therefore, a 
higher success rate per woman is expected in the future. 
Since transplantation techniques are being further optimized, 
a similar success rate to ovarian stimulation and cryopreser-
vation of oocytes could possibly achieved.
A case report has been published that reported a birth 
after the cryopreservation of ovarian tissue at the age of 
13 years (premenarchal) and a transplant at the age of 27 
[28]. This case report shows that transplantation can lead 
to pregnancies even after prepubertal cryopreservation of 
ovarian tissue. This is supported by two case reports, which 
have shown an induction of puberty by the transplantation of 
prepubertal cryopreserved ovarian tissue [22, 23].
Risks
The removal and transplantation of ovarian tissue requires 
a laparoscopy, the transplant another laparoscopy, possibly 
a laparotomy. When removing ovarian tissue, there is an 
increased risk of infection and bleeding depending on the 
oncological disease (e.g., in leukaemia patients). Accord-
ing to the FertiPROTEKT register, one complication per 
500 laparoscopies which necessitates surgical revision is 
expected for the removal of ovarian tissue [29]. The surgical 
risks for the transplantation of ovarian tissue are not higher 
than for any other laparoscopy.
Based on knowledge of the ovarian metastasis potential 
of oncological diseases and based on systematic studies of 
cryopreserved ovarian tissue, a preliminary, still incomplete 
risk category for ovarian metastases has been developed for 
individual oncological diseases (Table 2). In high-risk cases, 
cryopreservation of ovarian tissue should be considered as 
experimental and the patient should be informed that the 
tissue might not be used or can only be used after further 
establishment of the techniques mentioned below.
Practical approach
Removal of ovarian tissue
Before the removal of ovarian tissue, the ovarian reserve 
should be determined to avoid cryopreservation in women 
Table 2  Risks of ovarian metastasis ([56], modified)
Low risk Medium risk High risk
Breast cancer stage I–II and infiltrating ductal subtype
Squamous cell carcinoma of the cervix
Hodgkin’s lymphoma
Osteogenic carcinoma
Wilms tumour
Non-genital rhabdomyosarcoma
Breast cancer stage IV and infiltrating lobular subtype
Colon cancer
Adeno carcinoma of the cervix
Non-Hodgkin’s lymphoma
Ewing sarcoma
Leukaemia
Neuroblastoma
Burkitt lymphoma
Ovarian carcinoma
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with a low ovarian reserve. Ovarian tissue should not be 
taken from the side of the corpus luteum, as the quality of 
the ovarian tissue may be restricted.
Approximately 50% of the ovary is removed from the 
antimesenteric side using scissors without electrical coagu-
lation. In the FertiPROTEKT network, 50% of the ovarian 
tissue was removed in 97% of women [10]. The removal of 
an entire ovary is only recommended for prepubertal girls 
due to the small size of the ovaries. The wound surface is 
rinsed to identify the small, mostly subcortical sources of 
bleeding and to selectively coagulate them. A closure of the 
wound surface is not necessary. A small sample from the 
removed ovarian tissue is placed in formalin and handed to 
the pathologist to exclude metastases.
Transportation of tissue
The removed ovarian tissue should be transferred imme-
diately after removal into a sterile transport medium (e.g., 
Custodiol, Dr. Franz Köhler Chemie, Bensheim, Germany) 
and transported to the processing site at 4–8 °C. A transport 
time of up to 22 ± 2 h is possible with constant cooling at 
4–8 °C [30, 31], which can be ensured by the special cool-
ing packs and suitable transport containers provided by the 
respective cryobanks.
Preparation and freezing of ovarian tissue
A clean room laboratory with a contamination-free environ-
ment and a sterile class II lamina air flow should be available 
for preparation, where sterile and cooled dissection can be 
performed. The ovarian medulla should be carefully dis-
sected from the ovarian cortex using a precision scalpel and 
anatomical forceps and a thin residual stroma should be left, 
so that an optimal starting point for the neovascularization of 
the transplants is available later. Depending on the size and 
quality, rectangular pieces of cortex, ca. 8 × 4 × 1 mm, are 
cut from the prepared cortex, cooled in a suitable medium 
for cryopreservation, equilibrated, and then finally trans-
ferred to individual cryogenic vials filled with cryomedium. 
In a computer-controlled slow-freezing process, the samples 
are cooled according to a modified program by Gosden et al. 
[32], so that they can be stored indefinitely in liquid nitrogen 
(at – 196 °C).
Transplantation of ovarian tissue
The number of tissue fragments to be transplanted is deter-
mined using the ovarian reserve, and if possible the follicular 
density after histological determination, and the age of the 
patient at the time of removal of the tissue. The amount 
of ovarian tissue to be transplanted usually corresponds to 
approximately 15–25% of an entire ovary.
The ovarian tissue is mainly transplanted orthotopically, 
i.e., into the pelvic wall lateral to the ovaries, into or onto 
the ovary (Fig. 3). A transplant onto the ovary best imitates 
the physiological anatomy, but requires the greatest laparo-
scopic-microsurgical expertise and the duration of surgery 
(1–2 h) is the longest. A transplant into the pelvic wall is the 
least physiological localization, but surgically the easiest to 
perform and the operation only takes about ½–1 h. Which 
localization leads to the highest chances of pregnancy is still 
Ia  Ib  Ic  
IIa  IIb  III  
Fig. 3  Transplantation of ovarian tissue I: subperitoneally in the ovarian fossa (Ic: 12 months later), II: into the ovary, and III: onto the ovary 
(University women’s hospital, Bern, Switzerland)
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unclear. How much ovarian tissue should be transplanted is 
also still open to discussion. In the transplantations that led 
to a pregnancy in the FertiPROTEKT network [27], approxi-
mately 15–20% of the amount of an entire ovary was trans-
planted. During the transplantation, the patency of the tubes 
should be checked and, if necessary, a hysteroscopy should 
also be considered.
Transplantation into the pelvic peritoneum
A 0.5–1 cm incision is made in the parietal peritoneum lat-
eral to the ovary. A subperitoneal pocket is bluntly dissected 
and the pieces of tissue are placed, so that the cortex sur-
faces face the pelvis (Fig. 3, Ia). The pieces of tissue should 
lie side by side. Peritoneal closure is usually performed 
with single interrupted sutures (for example, with PDS 6-0) 
(Fig. 3, Ib), and with fibrin glue if necessary.
Transplantation into the ovary
The tissue is usually placed into the larger ovary and thus 
usually into the organ from which the ovarian tissue did not 
originate before gonadotoxic therapy. The ovary is incised 
(Fig. 3, IIa), ideally resulting in a subcortical pocket. The tis-
sue pieces are transplanted into the pocket, so that the cortex 
surfaces face the ovarian surface if possible. The closure of 
the ovary is usually performed with sutures (Fig. 3, IIb).
Transplantation onto the ovary
A transplant onto the ovary surface requires the tissue pieces 
to be of a sufficient size, so that they can be fixed. The ovary 
is, for example, incised on the surface using scissors, which 
opens a wound gap that is bluntly dilated. The tissue pieces 
can be fixed onto this with single interrupted sutures (e.g., 
with PDS 5-0) (Fig. 3, III). Fixation with fibrin glue and 
coverage with an  Interceed® mesh have also been reported 
[33]. A video demonstrating transplantation of ovarian tis-
sue into the peritoneal wall and onto the ovary is available 
at the Website of ESHRE (Special interest group “Fertility 
preservation”), http://www.eshre.eu.
Follow‑up after transplantation
The first signs of ovarian activity are seen after about 
3 months. If the tubes are open and no other relevant ste-
rility factor is present, a spontaneous pregnancy may be 
attempted. Cycle monitoring is often performed, ovulation 
is induced with hCG, and the timing of sexual intercourse is 
optimized. The many spontaneous pregnancies [27] confirm 
that spontaneous conception can initially be attempted. If 
a pregnancy does not occur or a different relevant sterility 
factor is present, then IVF, possibly combined with ICSI, 
can be carried out. Gonadotropin stimulation for the genera-
tion of several follicles can be attempted, but this often does 
not lead to a multifollicular reaction due to the low ovarian 
reserve and is also associated with higher costs. Alterna-
tively, a modified “Natural Cycle”-IVF can be performed 
[34].
According to the transplants in the FertiPROTEKT net-
work, approximately 2/3 of the transplants are still active 
after 1 year [27].
Since it is currently unclear which transplant location 
is ideal and how much tissue should be transplanted, the 
transplantation of ovarian tissue should only be carried out 
within the scope of clinical trials if possible. FertiPRO-
TEKT is conducting an open international multicentre study 
to determine the ideal transplant site (https://clinicaltrials.
gov/, NCT02780791).
GnRH agonists (GnRHa)
Background
The effect of GnRHa is based on the hypothesis that the 
resulting pituitary downregulation and “inactivation” of the 
ovarian activity would lead to a reduced sensitivity to cyto-
toxic effects. However, activation of the primordial to sec-
ondary follicles is gonadotropin-independent, so a protective 
influence cannot be plausibly explained this way [35]. Thus, 
the mode of action of GnRHa is currently unclear.
Efficacy
Most meta-analyses since 2011 showed a significantly lower 
rate of POI occurrence after chemotherapy-accompanying 
GnRHa administration. The risk can be reduced by about 
half, admittedly in a heterogeneous data situation [35–39]. 
A significant influence on the likelihood of a later pregnancy 
has not been proven so far. Demeestere et al. [40] published 
the first study on the long-term effect of GnRHa and were 
unable to demonstrate a benefit with a median follow-up of 
5.3 years after chemotherapy. There is currently still a need 
for clarification and the need for complementary prospective 
randomized studies on the use of GnRHa for this indication.
Risks
In principle, GnRHa can lead to climacteric symptoms such 
as hot flushes, etc. However, during chemotherapy, the ovar-
ian function is suppressed anyway, and such symptoms are 
possible a few days earlier at the most because of the previ-
ously administered GnRHa.
The irreversible loss of bone density, which is possi-
ble if GnRHa is administered for > 6 months, is normally 
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irrelevant here, as chemotherapy generally does not exceed 
this time. Regardless of this, it should be noted that GnRHa 
may theoretically affect the efficacy of chemotherapy on 
estrogen-sensitive tumours. This negative effect on chemo-
therapy has not been confirmed, however, but was rather 
disproved.
Practical approach
After the initial GnRHa application, a gonadotropin flare 
up is noted. However, whether this flare up is relevant is 
currently unclear, as the primordial follicles are not gon-
adotropin sensitive.
GnRHa are usually administered s.c. or i.m. as monthly 
or 3-monthly depots.
A depot-GnRHa should be repeatedly injected, so that the 
downregulation lasts about 1–2 weeks beyond the end of the 
last chemotherapy cycle.
Ovarian transposition
Background
The aims of ovarian transposition are the preservation of 
hormonal ovarian function and the possibility of preg-
nancy, even after oncological treatment. The effects of 
radiotherapy on ovarian function are considerable. A 
dose of 2 Gy to the ovaries (LD50) reduces the follicular 
density by half [41]. The dose for induction of a pre-
mature ovarian insufficiency in a 30-year-old woman is 
specified as 16 Gy [42]. Ovarian transposition should be 
considered when targeted radiotherapy is performed in 
the pelvic area. In addition to the benefits and risks, alter-
natives such as cryopreservation should be discussed. A 
combination of different fertility preservation techniques 
is also possible.
Ovarian transposition is not appropriate in patients who 
undergo total body irradiation. Pelvic radiotherapy is often 
performed in Hodgkin’s and non-Hodgkin’s lymphoma, 
rectal cancer, Ewing’s sarcoma of the pelvis, and cervical 
cancer.
The question of whether ovarian transposition should 
be performed prior to radiotherapy can only be decided 
individually. In addition to the expected gonadal toxic-
ity, the possible wish for a unilateral transposition plays a 
role to allow spontaneous conception via the remaining 
ovary.
Efficacy
The results of ovarian transposition before radiotherapy 
depend on various factors and are, therefore, difficult to 
quantify. In a meta-analysis of 32 publications with a total 
of 1189 patients, the success rate in the sense of preserved 
ovarian function is stated as 80.8% (17–95%) [43]. Publica-
tion bias is to be assumed, since many cases or studies with 
a poor success rate may not be published [44].
Furthermore, the success rate of ovarian transposition is 
also determined by the surgical technique. Different tech-
niques such as cranial, lateral, medial, and anterior trans-
position have been described [45]. Due to the inhomogene-
ity of the cases and the absence of prospective randomized 
studies, it is not possible to make a reliable statement on 
the comparison of the different techniques, whereby cranial 
transposition is the safest technique for reducing the dose 
of radiation.
However, the importance of the new position of the ova-
ries has been proven. The distance from the radiation field 
is decisive, since 10% of the radiation dose is still active at a 
distance of 10 cm from the radiation field [46]. Radiotherapy 
to the entire pelvis, despite transposition, is significantly 
more likely to lead to ovarian failure than localized after 
loading (35 versus 6%) [47]. In this respect, close collabora-
tion between the surgeon and radiologist is necessary before 
the planned transposition.
The positioning height of the ovary is also a relevant 
prognostic factor. In a multivariate analysis, the posi-
tioning height with an odds ratio of 11.7 was the most 
relevant prognostic factor for the ovarian function. The 
ovary should lie at least 2 cm above the iliac crest [48]. In 
addition, a safety margin of approximately 2 cm must be 
included, because the position of the ovaries can change 
postoperatively [49].
Overall, ovarian transposition is assumed to be highly 
effective in the sense of preserving ovarian function. How-
ever, pregnancies are rare [50]. On one hand, patients may 
no longer wish to have children after completing onco-
logical treatment [51]. On the other hand, radiotherapy to 
the uterus significantly reduces pregnancy chances. The 
radiation-induced alteration of the endometrium also influ-
ences the success rate of cryopreservation of the ovaries 
before radiotherapy.
Risks
The surgical risks of ovarian transposition are low. In 
most cases, the procedure is possible via laparoscopy. If 
laparotomy is performed because of another indication, 
ovarian transposition can be carried out simultaneously 
without a substantial increase in the complication rate. 
Ovarian tissue can also be removed during this procedure 
for cryopreservation. Ovarian cysts sometimes develop 
postoperatively which are a sign of disturbed ovarian 
function [43]. In most cases, however, these cysts do not 
require treatment.
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Practical approach
The infundibulum is prepared cranially until tension-free 
fixation of the ovary in the desired position is possible. 
Coagulation and/or torsion of the ovarian vessels must be 
avoided. Blood flow can be well controlled by inspection 
of the tube, whereas this is not possible with the ovary. The 
ovary is placed in the desired position, e.g., with single inter-
rupted sutures and marked with metal clips for radiotherapy 
planning. To avoid intestinal obstruction, the vascular pedi-
cle should also be fixed to the abdominal wall.
In vitro maturation und experimental techniques
There are numerous other techniques in addition to those 
mentioned. Most of these techniques are still experimental 
(Table 3). Only in vitro maturation (IVM) is also used in 
humans.
For IVM, the chances of success with a fresh transfer are 
relatively high in some centres. However, after additional 
oocyte cryopreservation, which is necessary for use as a fer-
tility preservation measure, the success rates are low. Cao 
et al. [52] reported that only 13% of in vitro-matured, cryo-
preserved, and fertilized oocytes developed into embryos 
compared to 33% without prior cryopreservation. Roesner 
et al. [53] reported only 2 births after 32 thawing cycles in 
61 cases where in vitro maturated oocytes had been cryopre-
served. IVM is, therefore, not very effective and should only 
be performed in women with a very high antral follicle count 
(AFC) and only if the 2 weeks required for gonadotropin 
stimulation mentioned above are not available.
Alternatively, IVM can be used to aspirate the oocytes 
from the follicles in ovarian tissue prior to its cryopreser-
vation. Huang et  al. [54], reported on 4 women, aged 
21–38 years. A partial oophorectomy was performed in 
3 women and a total oophorectomy in one. A total of 11 
oocytes were aspirated from the removed tissue of the 4 
women, of which 8 oocytes could be maturated and vitrified. 
Uzelac et al. [55] reported on a 23-year-old from whom 10 
immature oocytes were collected after an unilateral oopho-
rectomy; four of which were matured. The cryopreservation, 
however, only took place after fertilization of the oocytes. 2 
embryos were later transferred and a pregnancy developed 
that resulted in a birth. These and other case reports show 
that only very few oocytes can be collected from removed 
ovarian tissue. Furthermore, if the above-mentioned very 
low blastocyst development rates [52] and birth rates [53] 
are considered, it is evident that this method is not very 
effective.
Various techniques are being developed to enable the use 
of ovarian tissue in patients with haematological cancers 
with the purpose of avoiding the transmission of tumour 
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cells. However, these techniques, which are shown in 
Table 3, are still purely experimental.
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